Skip to content
Company Analysis

Standard BioTools Inc. LAB

A comprehensive view of key metrics, scores, and financial health for Standard BioTools Inc.

Overview of Standard BioTools Inc.

LAB NMS
Healthcare Medical Devices Small Cap
Standard BioTools Inc. (LAB), is a Small Cap company, in the Medical Devices industry, last closed at $0.93, about 96.8% overvalued vs fair value, -20.5% 1Y return, ranked 887/1110 in sector.
$0.93
0.00%
As of March 13, 2026
Previous close • Vol 90d: 63.5%
52-Week Range
Market Cap
$380.68M
Enterprise Value
$293.30M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Standard BioTools Inc..

Top Beats
No strong beats yet

Quick Facts

Website https://www.standardbio.com
HQ South San Francisco, CA
Employees 814
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $0.93 -97% vs base

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$85.3M
-51.1%%
Gross Profit
$42.5M
-49.5%%
Operating Income
$-93.3M
30.8%%
Net Income
$-74.9M
46.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
202.7%
Excellent

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
0/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Standard BioTools Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
31
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
39
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing LAB's balance between Growth (24.4%), Profitability (35.0%), and Safety (40.6%). Growth 24% Safety 41% Profitability 35%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

25th percentile vs peers
25
Key Signals
EPS Growth YoY 44.4% 63p Revenue CAGR 3Y -4.5% 17p Rev Growth YoY -51.1% 5p
Strengths
  • Strong liquidity position vs peers
Risks
  • Rev Growth Yoy in bottom 20% of peers (-51.1%)

Profitability

35th percentile vs peers
36
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

41th percentile vs peers
42
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Standard BioTools Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$0.03
- - -
-96.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info